Trial · NCT00218439

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

NCT00218439, Not applicable, Completed, University of Minnesota; results first posted 2014-05-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1. Trials, record NCT00218439. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00218439

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1
NCT number: NCT00218439
Status: Completed
Phases: Not applicable
Enrollment: 105 participants, actual
Lead sponsor: University of Minnesota
Conditions: Tobacco Use Disorder
Interventions: Paroxetine, Placebo
First posted: 2005-09-22
Last updated: 2019-11-01
Results first posted: 2014-05-23

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Systolic Blood Pressure Response to Stress	After 4 weeks of paroxetine / placebo	Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette
Other	Diastolic Blood Pressure Response to Stress	After 4 weeks of paroxetine / placebo	Change in diastolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette
Other	Heart Rate Response to Stress	After 4 weeks of paroxetine / placebo	Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette
Other	Plasma Epinephrine Concentration Response to Stress	After 4 weeks of paroxetine / placebo	Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette
Other	Plasma Norepinephrine Concentration Response to Stress	After 4 weeks of paroxetine / placebo	Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Systolic Blood Pressure Response to Stress	After 4 weeks of paroxetine / placebo	mmHg	MEAN
OTHER_PRE_SPECIFIED	Diastolic Blood Pressure Response to Stress	After 4 weeks of paroxetine / placebo	mm Hg	MEAN
OTHER_PRE_SPECIFIED	Heart Rate Response to Stress	After 4 weeks of paroxetine / placebo	beats/minute	MEAN
OTHER_PRE_SPECIFIED	Plasma Epinephrine Concentration Response to Stress	After 4 weeks of paroxetine / placebo	pg / ml	MEAN
OTHER_PRE_SPECIFIED	Plasma Norepinephrine Concentration Response to Stress	After 4 weeks of paroxetine / placebo	pg / ml	MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Systolic Blood Pressure Response to Stress	After 4 Weeks of Placebo	16.85	Standard Error 0.78	mmHg
Systolic Blood Pressure Response to Stress	After 4 Weeks of Paroxetine	11.71	Standard Error 0.78	mmHg
Diastolic Blood Pressure Response to Stress	After 4 Weeks of Placebo	9.78	Standard Error 0.49	mm Hg
Diastolic Blood Pressure Response to Stress	After 4 Weeks of Paroxetine	8.07	Standard Error 0.5	mm Hg
Heart Rate Response to Stress	After 4 Weeks of Placebo	20.39	Standard Error 0.56	beats/minute
Heart Rate Response to Stress	After 4 Weeks of Paroxetine	20.02	Standard Error 0.56	beats/minute
Plasma Epinephrine Concentration Response to Stress	After 4 Weeks of Placebo	40.98	Standard Error 3.42	pg / ml
Plasma Epinephrine Concentration Response to Stress	After 4 Weeks of Paroxetine	34.94	Standard Error 3.48	pg / ml
Plasma Norepinephrine Concentration Response to Stress	After 4 Weeks of Placebo	72.31	Standard Error 18.32	pg / ml
Plasma Norepinephrine Concentration Response to Stress	After 4 Weeks of Paroxetine	63.37	Standard Error 18.32	pg / ml

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention (4 Weeks)	STARTED	Placebo (4 Weeks) Then Paroxetine (4 Weeks)	58
First Intervention (4 Weeks)	STARTED	Paroxetine (4 Weeks) the Placebo (4 Weeks)	47
First Intervention (4 Weeks)	COMPLETED	Placebo (4 Weeks) Then Paroxetine (4 Weeks)	40
First Intervention (4 Weeks)	COMPLETED	Paroxetine (4 Weeks) the Placebo (4 Weeks)	35
First Intervention (4 Weeks)	NOT COMPLETED	Placebo (4 Weeks) Then Paroxetine (4 Weeks)	18
First Intervention (4 Weeks)	NOT COMPLETED	Paroxetine (4 Weeks) the Placebo (4 Weeks)	12
Second Intervention (4 Weeks)	STARTED	Placebo (4 Weeks) Then Paroxetine (4 Weeks)	40
Second Intervention (4 Weeks)	STARTED	Paroxetine (4 Weeks) the Placebo (4 Weeks)	35
Second Intervention (4 Weeks)	COMPLETED	Placebo (4 Weeks) Then Paroxetine (4 Weeks)	33
Second Intervention (4 Weeks)	COMPLETED	Paroxetine (4 Weeks) the Placebo (4 Weeks)	30

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events20

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dizziness	General disorders	During 4 Weeks of Placebo	1	62
other	Dizziness	General disorders	During 4 Weeks of Paroxetine	6	62
other	Gastrointenstinal symptoms	Gastrointestinal disorders	During 4 Weeks of Placebo	7	62
other	Gastrointenstinal symptoms	Gastrointestinal disorders	During 4 Weeks of Paroxetine	13	62
other	drowsiness	General disorders	During 4 Weeks of Placebo	10	62
other	drowsiness	General disorders	During 4 Weeks of Paroxetine	16	62
other	sexual side effects	Reproductive system and breast disorders	During 4 Weeks of Placebo	1	62
other	sexual side effects	Reproductive system and breast disorders	During 4 Weeks of Paroxetine	5	62
other	insomnia	General disorders	During 4 Weeks of Placebo	3	62
other	insomnia	General disorders	During 4 Weeks of Paroxetine	4	62

1 to 10 of 20Source ClinicalTrials.gov

See all 20 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	During 4 Weeks of Placebo
Total, all-cause mortality	During 4 Weeks of Paroxetine
Total, other adverse events	During 4 Weeks of Placebo	34	62
Total, other adverse events	During 4 Weeks of Paroxetine	35	62
Total, serious adverse events	During 4 Weeks of Placebo	0	62
Total, serious adverse events	During 4 Weeks of Paroxetine	0	62

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23504241	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
K23DA017307	Smoking, Antidepressants and Response to Mental Stress	KOTLYAR, MICHAEL	UNIVERSITY OF MINNESOTA	NATIONAL INSTITUTE ON DRUG ABUSE	2005 to 2009

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
During 4 Weeks of Paroxetine vs During 4 Weeks of Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00218439

GET https://conductscience.org/api/trials/v1/NCT00218439/registered

API reference For AI assistants